Therapies for Tau-associated neurodegenerative disorders: targeting molecules, synapses, and cells.

ABSTRACT: Advances in experimental and computational technologies continue to grow rapidly to provide novel avenues for the treatment of neurodegenerative disorders. Despite this, there remain only a handful of drugs that have shown success in late-stage clinical trials for Tau-associated neurodegenerative disorders. The most commonly prescribed treatments are symptomatic treatments such as cholinesterase inhibitors and N-methyl-D-aspartate receptor blockers that were approved for use in Alzheimer's disease. As diagnostic screening can detect disorders at earlier time points, the field needs pre-symptomatic treatments that can prevent, or significantly delay the progression of these disorders (Koychev et al., 2019). These approaches may be different from late-stage treatments that may help to amelio

SUBMITTER: Robbins M 

PROVIDER: S-EPMC10358644 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature